Table 1 The summary of MTTMJ patients’ clinico-pathologic characteristics
Variables | Disease specific survival (n = 611) | Overall survival (n = 734) | ||||
|---|---|---|---|---|---|---|
Alive (%) | Dead (%) | P-value | Alive (%) | Dead (%) | P-value | |
Gender | ||||||
Female | 198 (64.7%) | 108 (35.3%) | 0.67 | 199 (55.6%) | 159 (44.4%) | 0.711 |
Male | 203 (66.6%) | 102 (33.4%) | 203 (54%) | 173 (46%) | ||
Age | ||||||
≤ 44 (47) | 272 (81%) | 64 (19%) | 0.000 | 272 (74.9%) | 91 (25.1%) | 0.000 |
> 44 (47) | 129 (46.9%) | 146 (53.1%) | 130 (35%) | 241 (65%) | ||
Age period | ||||||
0–19 | 84 (83.2%) | 17 (16.8%) | 0.000 | 84 (77.1%) | 25 (22.9%) | 0.000 |
20–29 | 78 (83.9%) | 15 (16.1%) | 78 (79.6%) | 20 (20.4%) | ||
30–39 | 69 (80.2%) | 17 (19.8%) | 69 (74.2%) | 24 (25.8%) | ||
40–49 | 55 (75.3%) | 18 (24.7%) | 55 (65.5%) | 29 (34.5%) | ||
50–59 | 55 (66.3%) | 28 (33.7%) | 55 (36.4%) | 46 (45.5%) | ||
60–69 | 36 (49.3%) | 37 (50.7%) | 36 (36.4%) | 63 (63.6%) | ||
70–79 | 17 (28.3%) | 43 (71.7%) | 18 (22%) | 64 (78%) | ||
80+ | 7 (2.9%) | 35 (97.1%) | 7 (10.3%) | 61 (89.7%) | ||
Race | ||||||
Others | 59 (79.7%) | 15 (20.3%) | 0.001 | 59 (71.1%) | 24 (28.9%) | 0.000 |
Black | 88 (73.9%) | 31 (26.1%) | 88 (65.2%) | 47 (34.8%) | ||
White | 254 (60.8%) | 164 (39.1%) | 255 (49.4%) | 261 (50.6%) | ||
Pathological grade | ||||||
Grade I | 37 (38.5%) | 17 (31.5%) | 0.140 | 37 (56.1%) | 29 (43.9%) | 0.318 |
Grade II | 70 (69.3%) | 31 (30.7%) | 71 (56.8%) | 54 (43.2%) | ||
Grade III | 40 (53.3%) | 35 (46.7%) | 40 (45.5%) | 48 (54.5%) | ||
Grade IV | 45 (65.2%) | 24 (34.8%) | 45 (57.7%) | 33 (42.3%) | ||
AJCC Stage | ||||||
Stage I | 59 (92.2%) | 5 (7.8%) | 0.000 | 59 (86.8%) | 9 (13.2%) | 0.000 |
Stage II | 54 (74.0%) | 19 (77.8%) | 54 (65.1%) | 29 (34.9%) | ||
Stage III | 2 (22.2%) | 7 (77.8%) | 2 (20%) | 8 (80%) | ||
Stage IV | 6 (66.7%) | 3 (33.3%) | 6 (54.5%) | 5 (45.5%) | ||
T stage | ||||||
T1 | 33 (73.3%) | 12 (26.7%) | 0.324 | 33 (66%) | 17 (34%) | 0.721 |
T2 | 121 (81.8%) | 27 (18.2%) | 121 (72.9%) | 45 (27.1%) | ||
T3 | 14 (70%) | 6 (30%) | 14 (70%) | 6 (30%) | ||
T4 | 1 (50%) | 1 (50%) | 1 (50%) | 1 (50%) | ||
N stage | ||||||
N0 | 155 (82%) | 34 (18%) | 0.001 | 155 (74.2%) | 54 (25.8%) | 0.006 |
N1 | 5 (38.5%) | 8 (61.5%) | 5 (35.7%) | 9 (64.3%) | ||
NX | 9 (69.2%) | 4 (30.8%) | 9 (60%) | 6 (60%) | ||
M stage | ||||||
M0 | 163 (81.1%) | 38 (18.9%) | 0.003 | 163 (74.1%) | 57 (25.9%) | 0.001 |
M1 | 3 (42.9%) | 4 (57.1%) | 3 (30%) | 7 (70%) | ||
MX | 3 (42.9%) | 4 (57.1%) | 3 (37.5%) | 5 (62.5%) | ||
Surgery | ||||||
No | 31 (40.8%) | 45 (59.2%) | 0.000 | 31 (33.7%) | 61 (66.3%) | 0.000 |
Yes | 352 (74.9%) | 118 (25.1%) | 353 (62.8%) | 209 (37.2%) | ||
Radiotherapy | ||||||
No | 305 (70%) | 131 (30%) | 0.000 | 305 (57.3%) | 227 (42.7%) | 0.005 |
Yes | 86 (53.1%) | 76 (46.9%) | 84 (45.4%) | 101 (54.6%) | ||
Chemotherapy | ||||||
No | 295 (67.5%) | 142 (32.5%) | 0.122 | 295 (55.2%) | 239 (44.8%) | 0.673 |
Yes | 106 (60.9%) | 68 (39.1%) | 107 (53.5%) | 93 (46.5%) | ||